United States Patent 10,039,766: Scope, Claim Boundaries, and Landscape for Crystalline Form B
United States Drug Patent 10,039,766 claims use of a specific small-molecule active (S)-4-Amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]-pyrimidin-4-yl)piperidine-4-carboxamide in crystalline Form B, defined by X-ray powder diffraction (XRPD) peak sets, for treating breast cancer, prostate cancer, or gastric cancer, and it extends into formulation constraints (carriers/excipients and tablet composition/ratios).
This is a crystal-form-defined method-of-treatment patent. The practical enforcement boundary is not the therapeutic indication alone; it is the presence of crystalline Form B as proven by XRPD peaks at specified 2-theta values.
What is the core claim scope? (claims 1-4)
Active ingredient identity is fixed
All independent and dependent claims you provided are anchored to the same drug identity:
- (S)-4-Amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]-pyrimidin-4-yl)piperidine-4-carboxamide
This removes any design-around path based on salt selection or analog substitution inside the claim set you provided. If a competitor uses a different stereoisomer or modifies the scaffold, it leaves this claim family unless the competitor can argue equivalence under a doctrine not reflected in the claim text.
Indication coverage is broad within solid tumors
Claim 1 covers a method of treating three cancer types:
- breast cancer
- prostate cancer
- gastric cancer
There is no further staging, line of therapy, biomarker selection, or combination requirement in Claim 1 as provided. That means the claim language targets any patient “in need thereof” for those indications, provided the administered material meets the crystalline Form B XRPD definition.
Crystalline Form B is the decisive claim element
Claim 1 defines Form B via XRPD “at least three specific peaks”:
- at least three peaks at about 2-theta = 12.3°, 15.0°, and 19.2°
Dependent claims expand or tighten the XRPD peak requirements.
XRPD peak requirements by claim
| Claim |
XRPD definition boundary (2-theta, degrees) |
Threshold |
| 1 |
peaks at ~12.3°, 15.0°, 19.2° |
at least three peaks |
| 2 |
10.0, 12.3, 15.0, 17.1, 19.2, 24.4 |
all listed peaks (as “characterized by”) |
| 3 |
10.0, 12.3, 15.0, 15.5, 16.4, 17.1, 19.2, 23.9, 24.4, 26.0 |
at least ten listed peaks |
| 4 |
10.0, 5.0, 12.3, 15.0, 17.1, 19.2, 23.3, 24.4, 30.2, 32.3 |
at least ten listed peaks |
Enforcement impact: A product can infringe Claim 1 if it contains crystalline Form B with those three peaks present, even if additional peaks differ. Claims 2-4 are more specific: they require more comprehensive peak sets.
How “about” shifts infringement risk
All claim peak values are described with “about” in the provided text. That creates a tolerance window in practice. For invalidity and enforcement, peak matching typically turns into a laboratory/data question: what diffraction conditions, background subtraction, instrument calibration, and peak-picking rules were used, and how that affects whether peaks fall within the “about” tolerance.
For business decisions, the operational point is that Form B is defined by a spectral signature, not by a process step.
Where does the patent extend beyond the method claim? (claims 5-8)
Claims 5-8 shift from “administering a therapeutically effective amount of Form B” to specifying pharmaceutical compositions and tablet compositions.
Claim 5: composition with Form B + acceptable diluent
Claim 5 covers a pharmaceutical composition used for the method of claim 1:
- Formulation comprises crystalline Form B plus a pharmaceutically acceptable diluent or carrier
This claim is broad on excipient choice: it does not lock in specific amounts or an excipient list.
Claim 6: composition constrained to a specific excipient set
Claim 6 narrows the excipient selection:
- microcrystalline cellulose
- mannitol
- croscarmellose sodium
- magnesium stearate
Operationally, Claim 6 targets a standard direct-compression or wet-granulation tablet formulation profile.
Claim 7: tablet dose band
Claim 7 adds a tablet dose range:
- tablet contains 50 to 500 mg of the crystalline Form B active
- plus one or more excipients
This links drug content to the XRPD-defined Form B.
Claim 8: tablet excipient % ranges + ratio constraint
Claim 8 is the most specific formulation boundary.
It requires a tablet with:
- 0.5 to 2% by weight magnesium stearate
- 2 to 5% by weight croscarmellose sodium
- 15 to 60% by weight crystalline Form B
- microcrystalline cellulose + mannitol within a ratio of 3:1 to 1:1
- Form B amount within tablet: 50 to 500 mg
Claim 8 formulation boundary summarized
| Component |
Constraint |
| Magnesium stearate |
0.5% to 2% w/w |
| Croscarmellose sodium |
2% to 5% w/w |
| Form B active |
15% to 60% w/w and 50 to 500 mg per tablet |
| MCC:mannitol |
3:1 to 1:1 |
Enforcement impact: Claim 8 is a strong specificity lever for product-by-product infringement analysis. If a marketed tablet deviates materially in these percentages or the MCC:mannitol ratio, Claim 8 may not read on it even if the product uses Form B.
What is actually “invented” in claim language? (scope interpretation)
From the claim text alone, the “invention” scope is structured as:
- Drug scaffold and stereochemistry fixed: the (S)-enantiomer and full chemical identity are required.
- Crystal form fixed: Form B must meet XRPD peak inclusion thresholds.
- Use fixed: the method is “treating” three cancer indications.
- Delivery constraints extend outward: formulation and tablet composition constraints are layered in dependent claims.
This structure typically creates a two-tier infringement map:
- Tier A (broad): any method-of-treatment using Form B that matches the minimal XRPD requirement in Claim 1.
- Tier B (narrower): stricter XRPD peak sets (Claims 2-4) and tighter formulation compositions (Claims 6-8).
How should you read the XRPD claim boundaries in practice?
Peak sets act like claim “fingerprints”
- Claim 1 requires a subset fingerprint (three peaks).
- Claims 2-4 require superset or larger peak arrays.
Risk concentration for competitors
If a competitor’s Form B batch matches Claim 1’s three peaks, they can still face infringement even if they do not meet the full ten-peak definitions in Claims 2-4, because Claim 1 is independent.
Laboratory defensibility becomes central
XRPD claims turn infringement and validity disputes into spectral matching. In enforcement practice, the key questions are typically:
- which XRPD protocol is used
- peak picking and reporting rules
- whether amorphous content or polymorph mixtures reduce or mask peaks
- whether batch-to-batch variability shifts “about” peaks out of tolerance
In business terms, this means the most direct infringement pathway is not “same formulation idea.” It is “same crystal form signature in product.”
Patent landscape implications for freedom-to-operate (FTO)
This patent is likely to be policed at the crystalline-form level
Given the claims are crystal-signature-defined, the likely landscape posture around 10,039,766 is:
- other filings (either earlier or later in the same family) may claim:
- other polymorphs (Forms A, C, etc.)
- different solvates/hydrates
- amorphous material
- methods of preparing the specific crystal form
- additional medical indications or combinations
Even without those texts here, the claim design indicates enforcement leverage over manufacturing outcomes that yield Form B in final dosage forms.
Where design-around is most plausible, based on your claim set
Within the boundaries of what you provided, “easy” design-around routes look like one of the following (conceptually):
- avoid Form B and use a different solid form that does not match the required XRPD peaks
- change dosage form and excipients enough to avoid dependent formulation claims (Claims 6-8)
- use different indications (outside breast/prostate/gastric), if that aligns with commercial plan
But for FTO, the critical point is that Claim 1 can still be triggered by any product that contains Form B and is used for any of the three indications.
Claim-by-claim scope map (what is covered vs. what is not)
Claims 1-4: method-of-treatment read-through
| Covered subject |
Required elements |
| Treating breast/prostate/gastric cancer |
patient “in need,” therapeutically effective amount |
| Administered material |
the active as crystalline Form B |
| XRPD |
minimum peak set per claim (Claim 1: 3 peaks; Claims 2-4: expanded sets) |
Not covered by these claims (based on provided text):
- specific dosing schedules
- patient subgroups
- combination therapy requirements
- other cancer indications
Claims 5-8: pharmaceutical composition and tablet limits
| Claim |
Additional required formulation structure |
| 5 |
Form B + pharmaceutically acceptable diluent/carrier |
| 6 |
Form B + MCC + mannitol + croscarmellose sodium + magnesium stearate |
| 7 |
Form B tablet content 50-500 mg + excipients |
| 8 |
excipient % bands + MCC:mannitol ratio 3:1 to 1:1 + Form B 50-500 mg and 15-60% w/w |
Commercial and regulatory touchpoints that matter for enforcement
Even without external record details, the claims’ architecture points to practical friction points:
- Batch release testing: XRPD is typically a critical quality attribute for polymorph identity.
- ANDA/NDA comparability: if a generic seeks approval for the same active and strength, the crystalline form characterization becomes a central regulatory and litigation issue.
- Labeling and clinical use: if the product label includes the three covered indications, method-of-treatment exposure increases.
Key Takeaways
- 10,039,766 is a crystalline-form-defined patent: infringement hinges on whether the administered active is crystalline Form B meeting specified XRPD peak signatures.
- Claim 1 is the broadest hook: it requires only three XRPD peaks (about 2-theta 12.3°, 15.0°, 19.2°) tied to treatment of breast, prostate, or gastric cancer.
- Claims 2-4 tighten the crystal fingerprint by requiring larger peak arrays (including at least ten peaks in Claims 3-4).
- Dependent formulation claims constrain excipients and tablet composition: Claim 6 fixes an excipient set; Claim 8 adds exact % bands and an MCC:mannitol ratio.
- For competitive strategy, the most consequential variable is not tablet excipient selection alone; it is solid-state form identity under XRPD.
FAQs
1. What is the single most important element in Claim 1?
The administered drug must be the active in crystalline Form B, proven by an XRPD pattern with at least three specific peaks at about 2-theta 12.3°, 15.0°, and 19.2°, used to treat breast, prostate, or gastric cancer.
2. Can a product that matches the three-peaks set still infringe if it fails the ten-peak sets in Claims 2-4?
Yes. Claim 1 only requires the three-peak threshold. Claims 2-4 add stricter requirements but are dependent on Claim 1.
3. Do Claims 5-8 require the same cancer indication language as Claim 1?
They depend on the method framework of Claim 1, and the formulation limitations are structured as compositional elements tied to administering Form B as claimed.
4. What excipients are locked in by Claim 6?
Microcrystalline cellulose, mannitol, croscarmellose sodium, and magnesium stearate, together with crystalline Form B, plus pharmaceutically acceptable formulation context.
5. What is the hardest numerical constraint in Claim 8 for a tablet product?
The combination of:
- magnesium stearate 0.5% to 2% w/w,
- croscarmellose sodium 2% to 5% w/w,
- Form B 15% to 60% w/w and 50 to 500 mg per tablet, and
- MCC:mannitol ratio 3:1 to 1:1.
References (APA)
No external sources were provided or cited in your prompt beyond the claim text you supplied.
